Catalent Pharma Solutions will apply its drug delivery technology for the launch of three new products for Medipharm Industries, a Malaysian natural healthcare supplier. The companies worked together to develop new formulations for Medipharm’s recently launched Eurobio Vibrex Zinc-Plus, Bio-Vizmax and Bio-SMEDDS Q10 products, and Catalent will now act as sole supply partner. Catalent manufactures the products at its Braeside facility, near Melbourne, Australia, to cGMP and cGLP pharmaceutical standards.
“Catalent’s expertise in optimized formulation for the effective delivery of our products has enabled us to get these three new offerings to market quickly and efficiently,” said Medipharm’s managing director, CM Loh. “This was particularly useful in the case of Bio-SMEDDS Q10, where the enhanced bioavailability that Catalent was able to bring gives us a significant differentiating advantage over other CoQ10 formulations on the market.”
“Our expertise is all about helping our partners get better products to market faster,” said Michele Stokes, strategy and business development director at Catalent’s Braeside facility. “With a total population of more than 28 million, almost 65% of whom are aged between 15 and 64 years old, Malaysia offers significant growth opportunities for companies involved in the health care business and we are pleased to be working with Medipharm on these important products.”